Company / Depreciation & Amortization
Celldex Therapeutics, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$3.4M
FY2025
5-year range
$2.9M / $3.4M
FY2021-FY2025
Trend
+6.4%
vs FY2024
Sector context
#139 of 147
Health Care
What the data says
Among 147 Health Care companies, Celldex Therapeutics, Inc. is in the top 5% for depreciation & amortization. Depreciation & Amortization has increased for 3 consecutive years, from $3M in FY2022 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -3.0%.
Increased from $3M to $3M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +5.3%
- 5-Year CAGR
- -3.0%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 147This company $3.4M Sector average $338.5M
▼
-99.0% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s depreciation & amortization has grown for 3 consecutive years.
- 5-year CAGR of -3.0%, indicating a declining trend.
- In FY2025, depreciation & amortization increased 6.4% year-over-year.
- Ranks #139 out of 147 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.4M | +6.4% |
| FY2024 | $3.2M | +5.6% |
| FY2023 | $3.0M | +3.9% |
| FY2022 | $2.9M | -5.6% |
| FY2021 | $3.1M | -21.9% |
| FY2020 | $3.9M | -19.1% |
| FY2019 | $4.9M | +57.0% |
| FY2018 | $3.1M | -29.9% |
| FY2017 | $4.4M | +42.6% |
| FY2016 | $3.1M | +3.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026